Product Code: RP-ID-10346670 |
Published Date: 21 Oct 2022 |
Region: NA |
Category: Healthcare & Pharmaceuticals |
Report ID: 10346670
Market Overview:
Global Allergy Immunotherapy Market Size study, by Treatment (Subcutaneous Therapy (SCIT), Sublingual Therapy (SLIT)), Allergy (Allergic rhinitis, Allergic conjunctivitis, Allergic asthma, Stinging insect venom, Others), Distribution Channel (Hospitals, E-commerce, Pharmacy) and Regional Forecasts 2020-2027
Global Allergy Immunotherapy Market is valued approximately USD 2.9 billion in 2019 and is anticipated to grow with a healthy growth rate of more than 10.85 % over the forecast period 2020-2027. Allergy immunotherapy is a treatment for the avoidance of allergic reactions caused, among other factors, by fruit, grass pollen, dust, and bee venom. Among other common allergies, allergy immunotherapy helps control symptoms among people suffering from allergies such as rhinitis, asthma, and conjunctivitis. Immunotherapy for allergies requires daily doses that usually raise the dose in order to develop resistance in the patient. Due to the improved development of blocking antibodies that battle the foreign compounds that induce allergies, the patient's immune mechanism becomes less vulnerable with a gradual rise in dose. The market is driven by the prevalence of allergic diseases, Growing awareness about allergy care, High clinical R&D expenditure by governments and non-profit organizations. The key players of global Allergy Immunotherapy market have adopted various strategies to gain competitive advantage including product launch, mergers and acquisition, partnerships and agreements, investment, funding and others. For instance, In October 2017, DBV Technologies entered into an agreement with Stallergenes S.A. regarding research and development. For the prevention of allergies to birch. Additionally, The European Academy of Allergy and Clinical Immunology (EAACI) estimates that over 150 million people are actually suffering from chronic food allergies in Europe, representing 20 percent of the population of the country. Allergic rhinitis and asthma are the most common allergies, affecting 100 million and 70 million people, respectively. However, Global immunotherapy for allergies, the dearth of qualified practitioners, high procedure costs would restrain the market growth.
The regional analysis of global Allergy Immunotherapy Market is considered for the key regions such as Asia Pacific, North America, Europe, Latin America and Rest of the World. North America is the leading/significant region across the world in terms of growing awareness about allergy care, High clinical R&D expenditure by governments and non-profit organizations. Whereas, Asia-Pacific is also anticipated to exhibit highest growth rate / CAGR over the forecast period 2020-2027. Factors such as global allergy immunotherapy, the prevalence of allergic diseases would create lucrative growth prospects for the Allergy Immunotherapy Market across Asia-Pacific region.
Major market player included in this report are:
Stallergenes Greer
ALK
Allergy Therapeutics
Merck KGaA
HAL Allergy B.V.
Biomay AG
Anergis
Aimmune Therapeutics
Circassia
DBV Technologies
The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming eight years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within each of the regions and countries involved in the study. Furthermore, the report also caters the detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, the report shall also incorporate available opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:
By Treatment:
Subcutaneous Therapy (SCIT)
Sublingual Therapy (SLIT)
By Allergy:
Allergic rhinitis
Allergic conjunctivitis
Allergic asthma
Stinging insect venom
Others
By Distribution Channel:
Hospitals
E-commerce
Pharmacy
By Region:
North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE
Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Latin America
Brazil
Mexico
Rest of the World
Furthermore, years considered for the study are as follows:
Historical year – 2017, 2018
Base year – 2019
Forecast period – 2020 to 2027
Target Audience of the Global Allergy Immunotherapy Market in Market Study:
Key Consulting Companies & Advisors
Large, medium-sized, and small enterprises
Venture capitalists
Value-Added Resellers (VARs)
Third-party knowledge providers
Investment bankers
Investors
Stallergenes Greer
ALK
Allergy Therapeutics
Merck KGaA
HAL Allergy B.V.
Biomay AG
Anergis
Aimmune Therapeutics
Circassia
DBV Technologies
Related Reports
Proof of Quality & Reliability
